No Data
Betta Pharmaceuticals (300558.SZ) granted 1.6898 million restricted stocks to 171 incentive recipients.
betta pharmaceuticals (300558.SZ) announced that the company approved the "Regarding the Granting of 2023 Incentives to Incentive Objects...
Betta Pharmaceuticals Co., Ltd.'s (SZSE:300558) P/E Is Still On The Mark Following 26% Share Price Bounce
Betta Pharmaceuticals (300558.SZ) has had its masitinib included in the National Medical Insurance Catalog for first-line treatment indications.
Betta Pharmaceuticals (300558.SZ) announced that on November 28, 2024, according to the National Medical Insurance Administration and the Ministry of Human Resources and Social Security...
National medical insurance drug list unveiling soon! Keji Pharmaceutical's stock surged over 9%, leading the way in Hong Kong pharmaceutical stocks.
1. What is the importance of centralized procurement of pharmaceutical companies by medical insurance? 2. Which areas of products are expected to be included in the 2024 National Medical Insurance Drug Catalog?
Betta Pharmaceuticals (300558.SZ): The clinical center for ensartinib hydrochloride capsules has passed the on-site inspection by the FDA in the USA.
On November 22, Guanglianhui reported that Betta Pharmaceuticals (300558.SZ) announced that in March 2024, its holding subsidiary Xcovery Holdings, Inc. (hereinafter referred to as 'Xcovery') submitted a marketing authorization application for the hydrochloride ensartinib capsules (trade name: Beimina, hereinafter referred to as 'ensartinib') 'proposed for the treatment of local advanced or metastatic non-small cell lung cancer (NSCLC) patients with anaplastic lymphoma kinase (ALK) positive' (i.e., first-line indications) to the usa Food and Drug Administration.
Does Betta Pharmaceuticals (SZSE:300558) Have A Healthy Balance Sheet?
Betta Pharmaceuticals' (SZSE:300558) Earnings Have Declined Over Three Years, Contributing to Shareholders 62% Loss
No Data
